Advanced in Light Chain Deposition Disease (LCDD)

Dr. Joshua P. June

Rheumatology
4052 Legacy Parkway, 
Lansing, MI 
Accepting New Patients
Offers Telehealth
Advanced in Light Chain Deposition Disease (LCDD)
4052 Legacy Parkway, 
Lansing, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joshua June is a Rheumatologist in Lansing, Michigan. Dr. June is rated as an Advanced provider by MediFind in the treatment of Light Chain Deposition Disease (LCDD). His top areas of expertise are Psoriatic Arthritis, Undifferentiated Connective Tissue Disease (UCTD), Psoriasis, and Rheumatoid Arthritis (RA). Dr. June is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in MI
Hospital Affiliations
Edward W Sparrow Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Upper Peninsula Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Great Lakes Center of Rheumatology
4052 Legacy Parkway, Lansing, MI 48911

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Procedure, Device, Drug
Study Drug: Conventional Synthetic DMARD
Study Phase: Phase 3
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
View 3 Less Clinical Trials

1 Total Publications

Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: March 21, 2023
Similar Doctors
Advanced in Light Chain Deposition Disease (LCDD)
Dr. Ryan J. Massay
Rheumatology
Advanced in Light Chain Deposition Disease (LCDD)
Dr. Ryan J. Massay
Rheumatology

Regents Of The University Of Michigan

355 Briarwood Cir, 
Ann Arbor, MI 
 (55.3 miles away)
734-998-7710
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ryan Massay is a Rheumatologist in Ann Arbor, Michigan. Dr. Massay is rated as an Advanced provider by MediFind in the treatment of Light Chain Deposition Disease (LCDD). His top areas of expertise are VEXAS Syndrome, Ankylosing Spondylitis, Axial Spondyloarthritis (AxSpA), and Rheumatoid Pneumoconiosis. Dr. Massay is currently accepting new patients.

Experienced in Light Chain Deposition Disease (LCDD)
Dr. April L. Marquardt
Rheumatology
Experienced in Light Chain Deposition Disease (LCDD)
Dr. April L. Marquardt
Rheumatology

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (54.1 miles away)
734-936-5738
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

April Marquardt is a Rheumatologist in Ann Arbor, Michigan. Dr. Marquardt is rated as an Advanced provider by MediFind in the treatment of Light Chain Deposition Disease (LCDD). Her top areas of expertise are Neuroretinitis, Punctate Inner Choroidopathy, Scleritis, and Eales Disease. Dr. Marquardt is currently accepting new patients.

Experienced in Light Chain Deposition Disease (LCDD)
Dr. Katherine H. Chakrabarti
Rheumatology
Experienced in Light Chain Deposition Disease (LCDD)
Dr. Katherine H. Chakrabarti
Rheumatology

Advantage Health/saint Mary's Medical Group

1155 E Paris Ave Se, 100 Trinity Health Medical, 
Grand Rapids, MI 
 (50.9 miles away)
616-459-8088
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Katherine Chakrabarti is a Rheumatologist in Grand Rapids, Michigan. Dr. Chakrabarti is rated as an Advanced provider by MediFind in the treatment of Light Chain Deposition Disease (LCDD). Her top areas of expertise are Lupus Nephritis, Undifferentiated Connective Tissue Disease (UCTD), Sjogren Syndrome, and Perniosis. Dr. Chakrabarti is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. June's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 22 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile